Zobrazeno 1 - 10
of 118
pro vyhledávání: '"Paula R Pohlmann"'
Autor:
Yuan Yuan, Michael Klichinsky, Saar Gill, Melissa Johnson, Thomas Condamine, Jennifer Specht, Richard T Maziarz, Kim Reiss, Debora Barton, Daniel Cushing, Joanne Mortimer, Paula R Pohlmann, E Claire Dees, Naoto Ueno, Mathew Angelos, Ramona F Swaby, Yara Abdou
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/ac9f82ba4b6e4214881cf6857a725f08
Autor:
Edward T Richardson, Geoffrey I Shapiro, Jennifer L Guerriero, Claudine Isaacs, Filipa Lynce, Madeline G Townsend, Kelly F Zheng, Paula R Pohlmann, Kenichi Shimada, Arielle Heeke, Xue Geng, Candace Mainor, Mei Wei, Julie M Collins, Lauren M Sloat, Jane Staunton, Stuart J Schnitt, Joan S Brugge, Hongkun Wang
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/54cf98bb0cdd446684a18f53386d0e9d
Autor:
Amy T Shah, Michelle Demory Beckler, Alex J Walsh, William P Jones, Paula R Pohlmann, Melissa C Skala
Publikováno v:
PLoS ONE, Vol 9, Iss 3, p e90746 (2014)
Optical metabolic imaging measures fluorescence intensity and lifetimes from metabolic cofactors nicotinamide adenine dinucleotide (NADH) and flavin adenine dinucleotide (FAD). These molecular level measurements provide unique biomarkers for early ce
Externí odkaz:
https://doaj.org/article/98c9dbfc2d3b4e6d9b2e8bcd605ce861
Autor:
Hiromitsu Hatakeyama, Haixia Cheng, Pamela Wirth, Ashley Counsell, Samuel R Marcrom, Carey Burton Wood, Paula R Pohlmann, Jill Gilbert, Barbara Murphy, Wendell G Yarbrough, Deric L Wheeler, Paul M Harari, Yan Guo, Yu Shyr, Robbert J Slebos, Christine H Chung
Publikováno v:
PLoS ONE, Vol 5, Iss 9, p e12702 (2010)
We hypothesized that chronic inhibition of epidermal growth factor receptor (EGFR) by cetuximab, a monoclonal anti-EGFR antibody, induces up-regulation of its ligands resulting in resistance and that microRNAs (miRs) play an important role in the lig
Externí odkaz:
https://doaj.org/article/a0597c5a7e4e44f79420615c632dab7e
Autor:
Romualdo Barroso-Sousa, Paolo Tarantino, Nabihah Tayob, Chau Dang, Denise A. Yardley, Steven J. Isakoff, Vicente Valero, Meredith Faggen, Therese Mulvey, Ron Bose, Jiani Hu, Douglas Weckstein, Antonio C. Wolff, Katherine Reeder-Hayes, Hope S. Rugo, Bhuvaneswari Ramaswamy, Dan Zuckerman, Lowell Hart, Vijayakrishna K. Gadi, Michael Constantine, Kit Cheng, Frederick Briccetti, Bryan Schneider, Audrey Merrill Garrett, Kelly Marcom, Kathy Albain, Patricia DeFusco, Nadine Tung, Blair Ardman, Rita Nanda, Rachel C. Jankowitz, Mothaffar Rimawi, Vandana Abramson, Paula R. Pohlmann, Catherine Van Poznak, Andres Forero-Torres, Minetta Liu, Kathryn J. Ruddy, Yue Zheng, Shoshana M. Rosenberg, Richard D. Gelber, Lorenzo Trippa, William Barry, Michelle DeMeo, Harold Burstein, Ann Partridge, Eric P. Winer, Ian Krop, Sara M. Tolaney
Publikováno v:
npj Breast Cancer, Vol 8, Iss 1, Pp 1-7 (2022)
Abstract The excellent outcomes seen in patients treated with adjuvant trastuzumab emtansine (T-DM1) in the ATEMPT trial and the favorable toxicity profile associated with this agent make T-DM1 a potential therapeutic option for select patients with
Externí odkaz:
https://doaj.org/article/e88fcc1488804534afd42026e28dc869
Autor:
Douglas Yee, Claudine Isaacs, Denise M. Wolf, Christina Yau, Paul Haluska, Karthik V. Giridhar, Andres Forero-Torres, A. Jo Chien, Anne M. Wallace, Lajos Pusztai, Kathy S. Albain, Erin D. Ellis, Heather Beckwith, Barbara B. Haley, Anthony D. Elias, Judy C. Boughey, Kathleen Kemmer, Rachel L. Yung, Paula R. Pohlmann, Debu Tripathy, Amy S. Clark, Hyo S. Han, Rita Nanda, Qamar J. Khan, Kristen K. Edmiston, Emanuel F. Petricoin, Erica Stringer-Reasor, Carla I. Falkson, Melanie Majure, Rita A. Mukhtar, Teresa L. Helsten, Stacy L. Moulder, Patricia A. Robinson, Julia D. Wulfkuhle, Lamorna Brown-Swigart, Meredith Buxton, Julia L. Clennell, Melissa Paoloni, Ashish Sanil, Scott Berry, Smita M. Asare, Amy Wilson, Gillian L. Hirst, Ruby Singhrao, Adam L. Asare, Jeffrey B. Matthews, Nola M. Hylton, Angela DeMichele, Michelle Melisko, Jane Perlmutter, Hope S. Rugo, W. Fraser Symmans, Laura J. van‘t Veer, Donald A. Berry, Laura J. Esserman
Publikováno v:
npj Breast Cancer, Vol 7, Iss 1, Pp 1-8 (2021)
Abstract I-SPY2 is an adaptively randomized phase 2 clinical trial evaluating novel agents in combination with standard-of-care paclitaxel followed by doxorubicin and cyclophosphamide in the neoadjuvant treatment of breast cancer. Ganitumab is a mono
Externí odkaz:
https://doaj.org/article/784de0fabd374658a9d09088fa4a5ee8
Autor:
Katia Khoury, Antoinette R. Tan, Andrew Elliott, Joanne Xiu, Zoran Gatalica, Arielle L. Heeke, Claudine Isaacs, Paula R. Pohlmann, Lee S. Schwartzberg, Michael Simon, W. Michael Korn, Sandra M. Swain, Filipa Lynce
Publikováno v:
Frontiers in Oncology, Vol 10 (2020)
Background: PI3K/AKT signaling pathway is activated in breast cancer and associated with cell survival. We explored the prevalence of PI3K pathway alterations and co-expression with other markers in breast cancer subtypes.Methods: Samples of non-matc
Externí odkaz:
https://doaj.org/article/43bd68e948904f0aa92b8cf2a755899d
Autor:
Paula R. Pohlmann, Deena Graham, Tianmin Wu, Yvonne Ottaviano, Mahsa Mohebtash, Shweta Kurian, Donna McNamara, Filipa Lynce, Robert Warren, Asma Dilawari, Suman Rao, Candace Mainor, Nicole Swanson, Ming Tan, Claudine Isaacs, Sandra M. Swain
Publikováno v:
Breast Cancer Research and Treatment. 196:571-581
Purpose To assess whether crofelemer would prevent chemotherapy-induced diarrhea (CID) diarrhea in patients with HER2-positive, any-stage breast cancer receiving trastuzumab (H), pertuzumab (P), and a taxane (T; docetaxel or paclitaxel), with/without
Autor:
Arielle L Heeke, Andrew Elliott, Rebecca Feldman, Hazel F O'Connor, Paula R Pohlmann, Filipa Lynce, Sandra M Swain, Maria R Nunes, Daniel Magee, Matthew J Oberley, Jeffrey Swenson, Gregory Vidal, Claudine Isaacs, Lee Schwartzberg, W Michael Korn, Antoinette R Tan
Publikováno v:
Breast Cancer Research and Treatment. 196:279-289
Purpose:Estrogen receptor 1 (ESR1) mutations and fusions typically arise in patients with hormone receptor-positive breast cancer after aromatase inhibitor therapy, whereby ESR1 is constitutively activated in a ligand-independent manner. These varian
Autor:
Jerry Xiao, Paula R. Pohlmann, Claudine Isaacs, Benjamin A. Weinberg, Aiwu R. He, Richard Schlegel, Seema Agarwal
Publikováno v:
Biomedicines, Vol 9, Iss 9, p 1111 (2021)
Circulating tumor cells (CTCs) are single cells or clusters of cells within the circulatory system of a cancer patient. While most CTCs will perish, a small proportion will proceed to colonize the metastatic niche. The clinical importance of CTCs was
Externí odkaz:
https://doaj.org/article/5b9a8e9b7c424a1f850e9dd2e5308c37